Rewiring the inflammatory microenvironment to reverse ovarian failure: Immunomodulatory implications of finerenone

Recent evidence suggests that the nonsteroidal mineralocorticoid receptor (MR) antagonist finerenone restores folliculogenesis and fertility in premature ovarian insufficiency (POI) by reversing ovarian stromal fibrosis. While structural remodeling of the extracellular matrix (ECM) is a primary finding, this editorial highlights that chronic low-grade inflammation and immune dysregulation are fundamental drivers of fibrotic progression. We propose that the therapeutic success of finerenone reflects a critical "rewiring" of the inflammatory microenvironment. MR signaling in immune cells, such as macrophages and T lymphocytes, promotes proinflammatory phenotypes and the secretion of profibrotic mediators including TGF-β, IL-6, and TNF-α. By antagonizing MR, finerenone interrupts the self-reinforcing immune-fibrotic feedback loop, facilitating immunological recalibration toward a reparative state. This perspective positions the immune-fibrotic axis as a rational therapeutic target alongside traditional ECM remodeling. Future translational priorities should include detailed immune profiling and the integration of inflammatory biomarkers to refine clinical strategies. Ultimately, recognizing the inseparability of fibrosis and chronic inflammation will be essential for developing effective interventions to rescue organ function in POI and other inflammation-driven pathologies.